Skip to main content
Advertisement

AI Bias Analysis

4 models · Takes ~15 seconds

Bloomberg Markets

Biogen Buys Apellis for $5.6B to Expand Kidney Drugs

Biogen Buys Apellis for $5.6B to Expand Kidney Drugs
ShareXFacebook

Bloomberg's Michelle Davis joins Dani Burger on "Bloomberg Deals." Biogen has agreed to acquire Apellis Pharmaceuticals for $5.6 billion, expanding its treatments in immunology and rare diseases in one of the company’s largest-ever acquisitions. (Source: Bloomberg)

B

Source

Bloomberg Markets

Read full article at Bloomberg Markets

Opens original article in a new tab

Advertisement

Related Economy Stories

Advertisement